Cardiac Sarcoidosis: Oldies but Not Goodies by Sohn, Il-Suk
296
Print ISSN 1738-5520 / On-line ISSN 1738-5555
Copyright © 2011 The Korean Society of Cardiology
EDITORIAL
DOI 10.4070/kcj.2011.41.6.296
Open Access
Correspondence: Il-Suk Sohn, MD, Cardiovascular Center, Kyung Hee University Hospital at Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, 
Korea
Tel: 82-2-440-6108, Fax: 82-2-440-7242, E-mail: issohn@khu.ac.kr
• The author has no financial conflicts of interest.
cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licens-
es/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Refer to the page 313-320
Cardiac involvement in sarcoidosis is being increasingly 
noted since it has been recognized in the early 20th century 
and is associated with poor prognosis. Cardiac sarcoidosis is 
rare but is potentially fatal with a wide spectrum of clinical ma-
nifestations ranging from an incidentally discovered, benign 
condition to fatal cardiomyopathy, arrhythmias, and even sud-
den cardiac death.
1)2) Cardiac involvement may occur at any 
point during the course of sarcoidosis, may occur in the abs-
ence of pulmonary or systemic involvement, and may be a 
presenting feature.
1-3) Arrhythmias or conduction defects are 
the most common cardiac manifestations reflecting granu-
lomatous infiltration within the conduction system or ventri-
cular walls and are the most common causes of death due to 
cardiac sarcoidosis; however, progressive heart failure due to 
massive granulomatous infiltration of the myocardium ac-
counts for at least 25% of deaths.
1)3)4) Sarcoidosis can involve 
any part of the heart, including myocardium, endocardium, 
and pericardium.
3)4) The areas of involvement in descending 
order of frequency are the left ventricular free wall, ventricu-
lar septum, papillary muscles, right ventricle, and atria.
3) Obli-
teration of the sinoatrial node, atrioventricular node, or the 
bundle of his may occur.
4) Valvular dysfunction may result 
from localized involvement of the papillary muscles causing 
significant valvular insufficiency in rare cases.
4)
Diagnostic Challenge  
of Cardiac Sarcoidosis
Cardiac involvement in sarcoidosis has been extremely dif-
ficult to diagnose clinically because the clinical manifestations 
are non-specific, and the sensitivity and specificity of diagno-
stic modalities are limited. A resting electrocardiogram (ECG) 
is an appropriate screening test to order in all patients with 
confirmed or suspected sarcoidosis. Abnormalities on ECG 
including conduction disturbances, arrhythmias, or nonspe-
cific ST and T-wave changes can be demonstrated in up to 
one-third of sarcoid patients.
5) However, ECG remains a po-
orly sensitive test since the significance of these alterations 
and their relation to cardiac lesions and the patients’ symp-
toms are often unclear. Twenty-four-hour Holter monitoring 
and exercise ECGs can detect abnormalities even when rest-
ing ECGs are normal. Technetium-99m scintigraphy is more 
sensitive than thallium-201 scintigraphy. Both modalities 
exhibit the ‘‘reverse distribution’’ phenomenon (i.e., the focal 
defects detected in the resting phase of thallium scanning dis-
appear or decrease in size during thallium stress imaging or 
after dipyridamole infusion). These results are quite different 
from those observed in patients with coronary artery disease, 
in which defects are unchanged or enhanced after exercise or 
intravenous dipyridamole. Gallium-67 heart uptake predicts 
a better response to corticosteroid treatment. Contrast-enh-
anced magnetic resonance imaging and 18F-fluorodeoxy-
glucose positron emission tomography are most sensitive, and 
the findings seem to correlate with disease activity (Table 1).
2)6) 
An endomyocardial biopsy is preferable, but the procedure 
has a sensitivity as low as 20%.
1) 
Thus the search for a reliable, reproducible, and easily avail-
able diagnostic tool for cardiac sarcoidosis continues. A recent 
updated guideline was established in 2006 by the Japanese 
Ministry of Health and Welfare since it was first published 
in 1993 (Table 2).
6)7)
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Salient Features on Echocardiography
Echocardiography may be a useful imaging tool for myo-
cardial sarcoidosis. Echocardiographic abnormalities have 
been reported in patients with cardiac sarcoidosis, but the pre-
valence, spectrum, and clinical significance of echocardiogra-
phic findings are still unknown. Abnormalities seen on trans-
thoracic echocardiography, which include septal thinning, 
left ventricular regional systolic dysfunction, pericardial effu-
sion, ventricular aneurysms, left ventricular diastolic dysfunc-
tion, and valvular abnormalities, are usually seen in advanced 
disease and can be detected in only 14% of patients with sys-
temic sarcoidosis and cardiac involvement.
8) Cardiac lesions 
may also produce an increase in the thickness of the interven-
tricular septum, mimicking hypertrophic cardiomyopathy. 
This suggests that two dimensional echocardiography may 
not be sensitive enough to detect mild or small localized ab-
normalities, which may occur in the early stages of cardiac 
involvement.
In this issue of the Korean Circulation Journal, Sun et al.
9) 
reported that the prevalence of two characteristic echocar-
diographic findings suggesting cardiac sarcoidosis (basal sep-
tal thinning or localized aneurysmal dilatation without cor-
onary artery disease) in patients with pacemaker or impl-
antable cardiac defibrillator (ICD) was very low (1.2% in the pa-
cemaker group and 4.0% in the ICD group, 1.5% in the study 
subjects). And the prognosis was poor in patients with car-
diac sarcoidosis. Considering low yield of endomyocardial bio-
psy and rare systemic involvement in patients with cardiac sar-
coidosis, the authors suggest that echocardiographic find-
ings can be useful in the selected group of patients, as charac-
teristic basal septal thinning or aneurysmal dilatation can be 
regarded as a supporting evidence of cardiac involvement in 
sarcoidosis. The most important issue in cardiac sarcoidosis 
is the diagnostic difficulty and poor prognosis. As the authors 
have noted, clinical impact of diagnosis of cardiac sarcoido-
Table 1. Multimodality imaging for diagnosis of cardiac sarcoidosis
2)
Diagnostic test Feature Sensitivity Specificity
Electrocardiogram Conduction disturbances, arrhythmias Low Low
Echocardiography
Abnormal wall motion, regional wall thinning/thickening, 
  depressed ejection fraction, pericardial effusion
Low to moderate Low
201Thallium scintigraphy Segmental perfusion defect Moderate Moderate
67Gallium scintigraphy Increased myocardial uptake Low High
18F FDG-PET Increased myocardial uptake High Moderate to high
CMR High intensity lesions, thinning of ventricular wall Moderate to high High
FDG-PET: fluorodeoxyglucose positron emission tomography, CMR: cardiac magnetic resonance
Table 2. Updated guideline for diagnosis of cardiac sarcoidosis by the Japanese Ministry of Health and Welfare in 2006
6)
Histologic diagnosis group
Cardiac sarcoidosis is confirmed when endomyocardial biopsy specimens demonstrate noncaseating epithelioid cell granulomas with
  histological or clinical diagnosis of extracardiac sarcoidosis.
Clinical diagnosis group
Although endomyocardial biopsy specimens do not demonstrate noncaseating epithelioid cell granulomas, extracardiac sarcoidosis 
  is diagnosed histologically or clinically and satisfies the following conditions and more than one in six basic diagnostic criteria.
   1. 2 or more of the 4 major criteria are satisfied.
   2. 1 in 4 of the major criteria and 2 or more of the 5 minor criteria are satisfied.
Major criteria
   1. Advanced atrioventricular block.
   2. Basal thinning of the interventricular septum.
   3. Positive 
67gallium uptake in the heart.
   4. Depressed ejection fraction of the left ventricle (<50%).
Minor criteria
   1.   Abnormal ECG findings: ventricular arrhythmias (ventricular tachycardia, multifocal or frequent PVCs), CRBBB, axis deviation  
 or abnormal Q-wave.
   2. Abnormal echocardiography: regional abnormal wall motion or morphological abnormality (ventricular aneurysm, wall thickening).
   3. Nuclear medicine: perfusion defect detected by 
201thallium or 
99mtechnetium myocardial scintigraphy.
   4. Gadolinium-enhanced CMR imaging: delayed myocardial enhancement.
   5. Endomyocardial biopsy: interstitial fibrosis or monocyte infiltration over moderate grade.
CMR: cardiac magnetic resonance, CRBBB: complete right bundle branch block, ECG: electrocardiogram, PVC: premature ventricular con-
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sis based on combination of both the clinical features of signi-
ficant arrhythmias warranting device therapy and the charac-
teristic echocardiographic findings needs to be tested in fut-
ure investigations.
In conclusion, clinicians should consider the possibility of 
cardiac sarcoidosis in the evaluation of an otherwise healthy 
young patient who develops unexplained cardiomyopathy or 
arrhythmias. Given the grave prognosis of cardiac sarcoid-
osis, cardiac signs or symptoms in a patient with known sar-
coidosis should alert the physician to perform an aggressive 
workup including ECG screening and multimodality imag-
ing for confirming the diagnosis of cardiac sarcoidosis. 
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